A novel antibody-TCR (AbTCR) platform combines Fab-based antigen recognition with gamma/delta-TCR signaling to facilitate T-cell cytotoxicity with low cytokine release

The clinical use of genetically modified T-cell therapies has led to unprecedented response rates in leukemia and lymphoma patients treated with anti-CD19 chimeric antigen receptor (CAR)-T. Despite this clinical success, FDA-approved T-cell therapies are currently limited to B-cell malignancies, and...

Descripción completa

Detalles Bibliográficos
Autores principales: Xu, Yiyang, Yang, Zhiyuan, Horan, Lucas H., Zhang, Pengbo, Liu, Lianxing, Zimdahl, Bryan, Green, Shon, Lu, Jingwei, Morales, Javier F., Barrett, David M., Grupp, Stephan A., Chan, Vivien W., Liu, Hong, Liu, Cheng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6242878/
https://www.ncbi.nlm.nih.gov/pubmed/30479831
http://dx.doi.org/10.1038/s41421-018-0066-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6242878/
https://www.ncbi.nlm.nih.gov/pubmed/30479831
http://dx.doi.org/10.1038/s41421-018-0066-6

Ejemplares similares